(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA), today, is announcing a new ad campaign, “Drug Manufacturers are Pointing Fingers…Again.” With Congress poised to permanently repeal the rebate rule and prevent significant increases in both Medicare beneficiary premiums and Medicare
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new report, “Drug Manufacturer Strategies for Keeping Drug Costs High,” on pharmaceutical industry pricing tactics that increase prescription drug costs for patients. The report, conducted by the research firm Visante,
(Washington, D.C.) — Senior registered voters enrolled in Medicare Part D will be less likely to support the reelection of their members of Congress and presidential candidates if those elected officials back proposals eliminating prescription drug negotiations and price concessions
As the debate on high-cost prescription drugs continues and policymakers seek solutions to reduce out-of-control prices for consumers, the Pharmaceutical Care Management Association (PCMA) today is announcing the launch of a new, multi-faceted digital public affairs campaign OnYourRxSide. The campaign is designed
(Washington, D.C.) — A new white paper, “Solving America’s High Drug Cost Problem: Prevent Drug Company Tactics that Increase Costs and Undermine Clinical Quality,” by the Pharmacy Benefit Management Institute (PBMI), released today by the Pharmaceutical Care Management Association (PCMA),
(Washington, D.C.) — As the Administration considers modifying price concessions for prescription drugs in Medicare and federal programs, the Pharmaceutical Care Management Association (PCMA) is releasing new data, “Reconsidering Drug Prices, Rebates, and PBMs,” showing drug manufacturers alone set prices –
(Washington, D.C.) — As part of its OnYourRxSide campaign, the Pharmaceutical Care Management Association (PCMA) today released a new video — “What is a PBM?” — detailing the role pharmacy benefit managers (PBMs) play in the prescription drug supply chain
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on a new Milliman report on insulin coverage in Medicare Part D. A new report conducted by the actuarial firm Milliman, “A Summary of Insulin Coverage in
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) unveiled a new campaign commending the Biden Administration for delaying the Medicare prescription drug rebate rule, while calling for a complete Congressional repeal. “We applaud the Biden Administration for delaying the
(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Congressional Budget Office’s (CBO) scoring of the Health and Human Services Office of Inspector General’s proposed rule revising the safe harbors around
©2024 PCMA. All Rights Reserved.
